| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335720 | Transfusion and Apheresis Science | 2010 | 6 Pages |
BackgroundUmbilical cord blood (UCB) is a valid alternative to be used in transplanted patients.Limitations of the use of stem cells depends on the small number of cells available; this is the reason why UCB can be used only in very low-weight patients.In this study we have evaluated the efficacy of cellular manipulation before transplant and in particular, before thawing the units through the Rubinstein method.MethodsWe have evaluated the results obtained after thawing 40 UCB to be used for as many patients affected by several pathologies (21 ALL, 6 AML, 3 MDS, 2 LNH, 2 histiocytosis, 2 β-thalassemia, 1 Chédiak-Higashi syndrome, 1 Fanconi anemia, 1 Wiskott-Aldrich syndrome and 1 Omenn syndrome).ResultsAfter thawing, nucleated cells (NC) mean recovery was 76.81% (SD ± 15.41). The quantity of NC obtained was 124.29 × 107 (SD ± 43.18) and in only 5 cases the number of NC after the procedure was lower than the requested graft dose. Among the last ones, in two cases only we did not achieve the target after manipulation. The post-manipulation cellular viability was 83.48% (SD ± 10.6). For all the units shipment complied with all the necessary procedures; in fact the temperature never rose above −120 °C.ConclusionIn our study we highlighted the efficacy of UCB thawing technique, with the same method defined in 1995 at the New York Blood Centre that guarantees an excellent NC recovery and maintains a high level of cell viability.
